| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Operating activities | ||||||||
Net loss | ||||||||
-19,595 | -14,789 | -12,912 | -13,793 | -14,250 | -1,493 | -10,237 | -11,541 | -12,046 |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||||||||
Depreciation and amortization | ||||||||
1,099 | 1,217 | 1,231 | 1,192 | 1,137 | 1,135 | 1,119 | 1,123 | 1,162 |
Accretion of discount on marketable securities | ||||||||
41 | 129 | 65 | 663 | 600 | 361 | 166 | 0 | 0 |
Stock-based compensation | ||||||||
2,707 | 2,683 | 2,880 | 2,463 | 2,286 | 2,070 | 321 | 217 | 264 |
Recognition of expense (income) on derivative liability | ||||||||
-7 | - | - | - | 127 | - | - | - | - |
Reduction of the liability attributable to a research, development and commercialization agreement | ||||||||
- | - | - | - | - | - | - | - | 0 |
Accretion of debt discount | ||||||||
- | - | - | - | - | - | - | - | 38 |
Revaluation of SutroVax option liability | ||||||||
- | - | - | - | - | - | - | - | 0 |
Other | ||||||||
19 | -111 | 34 | -43 | -73 | -30 | -343 | 71 | -35 |
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | ||||||||
2,781 | -1,233 | 1,031 | 3,162 | 849 | 46 | -741 | -971 | 2,531 |
Prepaid expenses and other assets | ||||||||
-1,417 | 1,533 | 314 | -70 | -336 | 1,319 | 640 | 131 | 130 |
Accounts payable | ||||||||
- | 776 | 168 | 833 | 476 | 344 | 515 | -461 | -189 |
Accrued compensation | ||||||||
-3,073 | 1,389 | 1,063 | 1,063 | -3,715 | 2,132 | 6 | -540 | 980 |
Other liabilities | ||||||||
-745 | 366 | -283 | -294 | 397 | -546 | 1,007 | 46 | 44 |
Deferred rent | ||||||||
36 | 25 | 22 | 13 | 7 | -3 | -8 | -16 | -21 |
Deferred revenue | ||||||||
2,326 | -4,439 | -6,858 | -3,587 | -5,302 | -6,861 | 54,488 | -2,664 | -2,658 |
Net cash used in operating activities | ||||||||
-18,734 | -13,156 | -16,121 | -15,601 | -20,145 | -5,935 | 47,573 | -13,945 | -15,010 |
Investing activities | ||||||||
Purchases of marketable securities | ||||||||
3,600 | 4,509 | 44,347 | 28,317 | 119,053 | 7 | 81,456 | 0 | 0 |
Maturities of marketable securities | ||||||||
37,500 | 14,500 | 41,826 | 34,500 | 37,750 | 2,750 | 0 | 0 | 0 |
Sales of marketable securities | ||||||||
8,500 | 0 | 13,000 | 3,500 | 3,500 | - | 0 | 0 | 0 |
Purchases of equipment | ||||||||
763 | - | 667 | 489 | 276 | - | 359 | 36 | 364 |
Net cash provided by (used in) investing activities | ||||||||
41,637 | 7,942 | 9,812 | 9,194 | -78,079 | 2,025 | -81,815 | -36 | -364 |
Financing activities | ||||||||
Proceeds from debt refinancing | ||||||||
25,000 | - | - | - | - | - | - | - | - |
Payment of deferred offering costs | ||||||||
- | - | - | - | - | - | 1,879 | 482 | 52 |
Payments of debt | ||||||||
10,000 | 1,500 | 1,500 | 1,500 | 500 | - | 0 | 0 | 0 |
Proceeds from exercise of common stock options | ||||||||
56 | - | - | 10 | 42 | - | - | 36 | 38 |
Proceeds from employee stock purchase plan | ||||||||
646 | - | - | - | - | - | - | - | - |
Net cash provided by (used in) financing activities | ||||||||
15,702 | -1,780 | -1,127 | -819 | -458 | 87,855 | 50,175 | 32,769 | -14 |
Net increase (decrease) in cash, cash equivalents and restricted cash | ||||||||
38,605 | - | - | - | -98,682 | - | - | - | - |
Net (decrease) increase in cash, cash equivalents and restricted cash | ||||||||
- | - | - | - | - | - | - | 18,788 | -15,388 |
Supplemental disclosure of cash flow information: | ||||||||
Cash paid for interest | ||||||||
134 | 151 | 265 | 303 | 330 | 333 | 326 | 316 | 300 |
Supplemental disclosure of non-cash investing and financing information: | ||||||||
Purchase of property and equipment included in accounts payable | ||||||||
255 | 259 | -135 | 83 | 63 | -405 | 573 | 32 | 5 |
Deferred initial public offering costs included in accounts payable | ||||||||
- | - | - | - | - | - | 1,005 | 601 | 53 |
Embedded interest associated with program fees | ||||||||
600 | 667 | 760 | 857 | 860 | - | 0 | 0 | 0 |
Warrants issued to lenders as part of debt discount | ||||||||
619 | - | - | - | - | - | - | - | - |
Vesting of early exercised shares | ||||||||
- | - | - | - | - | - | - | - | 14 |